Fast movers • Alerts • Momentum
10% OFF with SAVE10
Charts • Watchlists • Multi-broker tools
Built for active traders
Biotech catalyst, news and analysis PDUFA tracker
Biotech catalyst, news and analysis PDUFA tracker
Maze trades as a high-expectations play on APOL1-mediated kidney disease: the stock has rerated into a roughly mid-cap valuation on the back of a very strong balance sheet and the upcoming proof-of-concept data from the HORIZON Phase 2 trial in a broad AMKD population. The key tension now is simple: can the first substantive MZE829 dataset justify how far the share price has already come.
In January you saw the “National Defense Strategy / Deep Tech” macro piece: defense budgets, uranium enrichment, electronic warfare and reusable launch infrastructure all moving at once. In that map, AST SpaceMobile sits on the space-based connectivity layer: a company trying to build cell towers in orbit that can serve both civilian and military customers, at a time when governments explicitly talk about resilient communications, contested environments and independent infrastructure. This note takes that macro lens and zooms back into ASTS.
The FDA has sent a Complete Response Letter (CRL) for RGX-121 (clemidsogene lanparvovec) in MPS II, rejecting the BLA under the accelerated approval pathway and questioning the external control, the neuronopathic eligibility criteria and the CSF HS D2S6 biomarker. Management plans a Type A meeting and aims to resubmit, but the ultra-rare MPS II path is now longer and more complex, against a backdrop of recent clinical holds on the company’s ultra-rare MPS programs.
Quince Therapeutics has announced that it has engaged LifeSci Capital as its exclusive financial advisor to assist with a restructuring process and a formal review of “strategic alternatives” with the stated goal of maximizing shareholder value. The menu of options explicitly listed by the company includes partnerships, joint ventures, mergers, acquisitions, licensing deals or other strategic transactions, and LifeSci will also support any restructuring of the company’s liabilities.
Ensysce Biosciences has provided a new operational update on its pivotal Phase 3 trial PF614-301, which evaluates PF614, a next-generation oxycodone prodrug, in patients with moderate to severe acute pain following abdominoplasty surgery. The company reports that the study has now enrolled 50% of the subjects targeted for the planned interim review, a meaningful operational milestone for a small clinical-stage pain company trying to move an abuse- and overdose-resistant opioid toward the market.
From FDA approval of Symvess for vascular trauma to Ukrainian war-zone data and fresh U.S. support for biologic vascular repair, Humacyte is trying to turn a once “sci-fi” idea – off-the-shelf human vessels grown in a factory – into something routine in emergency rooms and military hospitals.
Potential resubmission of the supplemental BLA for BCG-unresponsive papillary NMIBC following the January 20 FDA meeting. The company committed to deliver additional analyses within 30 days, without new clinical trials. If the resubmission is accepted, the review clock could define the next major run-up window.
Biofrontera (BFRI) – Positive Phase 3 trunk/extremities data for Ameluz PDT, sharp micro-cap sell-off
Biofrontera reports that its Phase 3 study of Ameluz® PDT for actinic keratoses on the extremities, neck and trunk met the primary endpoint, strengthening the case for a 2026 sNDA – but the stock trades lower intraday, reminding investors how noisy tiny-cap price action can be.
Protara Therapeutics (TARA) — TARA-002 Phase 2 NMIBC catalyst at the end of February 2026
Protara Therapeutics is a small-cap biotech that has quietly moved from “option on survival” to a fully funded late-stage story built around a single, high-leverage asset: TARA-002. The drug is a TLR2/NOD2 agonist derived from the same cell bank as the long-used immunotherapy OK-432 (Picibanil) and is being developed both for non-muscle invasive bladder cancer (NMIBC) and for pediatric lymphatic malformations. The near-term catalyst now staring at the tape is an updated Phase 2 read-out in BCG-unresponsive NMIBC that will be presented on 27 February 2026 and that the company itself frames as aligned with the registrational pathway for this setting.
The Singapore Airshow 2026 is not just a nice backdrop for air displays and static jets. It is a live x-ray of how fast the Indo-Pacific balance of power is shifting, and how quickly drones and AI-enabled systems have moved from the fringe to the centre of the defence conversation. While China shows off fighters and commercial jets to signal that it wants a bigger slice of the regional market, US and allied firms are quietly doing something just as important: locking in long-term positions across drones, autonomy and “AI-ready” hardware.
For years, “space” was mostly a story about launch costs and broadband dreams. In 2026 the narrative is shifting: satellites are becoming the nervous system of a new defence architecture built around missile warning, tracking and resilient communications
Cognition Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative, small-molecule oligomer antagonists for age-related degenerative disorders of the central nervous system, primarily Alzheimer's disease (AD) and Dementia with Lewy Bodies (DLB).
Clinical-stage oncology company focused on bispecific antibodies that couple angiogenesis and immune modulation.
KOD
Kodiak Sciences Inc.
Late-stage retina biotech riding a multi-hundred-percent run-up into a dense 2026–2027 catalyst cluster (tarcocimab, KSI-501 and KSI-101). Chart from Finviz, always double-check the latest quote and news.
Deep dive on Ocular Therapeutix: from DEXTENZA to the late-stage AXPAXLI retina franchise, with SOL-1 topline data in wet AMD coming in late February 2026 and a balance sheet funded into 2028.
Week of 9–15 February 2026 – the setup is unusual: the U.S. government shutdown pushed key releases into the same week, so the market gets a jobs + CPI combo while earnings keep dictating leadership.
A year ago, Agios was still mostly a “promise stock”: one approved niche drug for pyruvate kinase deficiency and a lot of hope around sickle cell disease. Today the picture is more complex but also more concrete: mitapivat now has two U.S. approvals, a full rare-disease haematology franchise is forming, and 2026 has a surprisingly busy catalyst map.
First-in-human data for the nPulse™ Cardiac Catheter Ablation System show high pulmonary vein isolation durability and low SAE rate in atrial fibrillation – but this is still a pre-commercial, single-platform story.
Gene therapy for ultra-rare immunodeficiency (LAD-I), a hard reset after last year’s CRL and the Danon shock, and a March 28, 2026 PDUFA that could flip sentiment in a name now trading near multi-year lows. This is a classic “platform vs. execution” test in gene therapy – with an additional potential upside lever in the form of a Rare Pediatric Disease Priority Review Voucher (PRV) if approval comes through.
Rigetti is one of the few pure-play public quantum computing hardware names. It designs and manufactures superconducting quantum processors, integrates the control stack and cryogenics around them, and exposes these systems through a cloud platform so that enterprises, governments and researchers can experiment with quantum algorithms and hybrid quantum-classical workflows.